Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with rpe65 mutation in switzerland

HIGHLIGHTS

• who: Arjun Bhadhuri from the Switzerland Switzerland SwitzerlandInstitute of Pharmaceutical Medicine (ECPM), University of Basel have published the research: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland, in the Journal: (JOURNAL)
• what: The authors aimed to evaluate the cost-effectiveness of voretigene neparvovec (VN) compared with standard of care (SoC) for patients with inherited retinal disease (IRD) caused by a biallelic RPE65-mutation. The aim of this study was to assess the cost-effectiveness of VN in the Swiss setting, from a healthcare system . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.